Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

Bosutinib (SKI-606) is an orally available, once-daily, dual Src and Abl kinase inhibitor with promising clinical potential in first-, second-, and third-line treatment of chronic myeloid leukemia (CML). Bosutinib effectively inhibits wild-type BCR-ABL and most imatinib-resistant BCR-ABL mutations e...

Descripción completa

Detalles Bibliográficos
Autores principales: Amsberg, Gunhild Keller-von, Koschmieder, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594007/
https://www.ncbi.nlm.nih.gov/pubmed/23493838
http://dx.doi.org/10.2147/OTT.S19901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594007/
https://www.ncbi.nlm.nih.gov/pubmed/23493838
http://dx.doi.org/10.2147/OTT.S19901

Ejemplares similares